SCHEMBL15224110

SCHEMBL15224110

CN(Cc1cccc2ccccc12)C(=O)CCN

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
METAP2 P50579 8/20 0.52
METAP1 P53582 4/20 0.50
MC4R P32245 1/20 0.50
MC5R P33032 1/20 0.50
MC3R P41968 1/20 0.50
MC1R Q01726 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NLN Q9BYT8 2/20 0.48
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15224271 0.93 MC4R (0.56) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL15224270 0.88 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL15224109 0.84 CYP1A2 (0.54) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL8303717 0.83 MC4R (0.51) CYP1A2CYP2D6CYP2C19METAP2MC4R
SCHEMBL23972323 0.81 CYP1A2 (0.62) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL9240681 0.78 TACR1 (0.54) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL26027575 0.78 METAP2 (0.62) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL5713026 0.77 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL5647636 0.77 PDK1 (0.57) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL4020831 0.77 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C19METAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CYP1A2 167/4885CYP2D6 395/4885CYP2C19 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.